Socioeconomic relevance of selected treatment strategies in patients with chronic heart failure.
More than 2.8% of the population in the USA suffer from chronic heart failure, a condition that primarily afflicts people above the age of 60 years, and results in major expenses for social and health care of affected patients, their caregivers and families. The mainstay of treatment is drug therapy, complemented by comprehensive rehabilitation, invasive procedures, palliative treatment and monitoring. While sufficient health economic evidence exists on the cost-effectiveness of certain standard drugs, such as angiotensin converting enzyme inhibitors or beta-blockers, little or no information exists on the cost effectivty of diuretics or aldosterone antagonists. Recently, introduced treatment strategies such as ventricular assistance devices or telemonitoring have yet to be evaluated for their cost-effectiveness in terms of risk of hospitalization, life expectancy and quality of life. With respect to the aging population and the drastically increasing costs of healthcare for heart failure patients, the goal is a more conscious and cost-effective resource allocation. This can help reduce the incidence of over and under treatment, diminish side effects and consequently improve symptoms, quality of life and life expectancy in the affected population. Further clinical trials and health economic analyses are necessary to optimize recommendations for healthcare of patients with chronic heart failure.
Rychlik
Reinhard
R
Institute of Empirical Health Economics, Am Ziegelfeld 28, 51 399 Burscheid, Germany. reinhard.rychlik@ifeg.de
Rulhoff
Hanna
H